- Knight Therapeutics (GUD:CA) announced on Thursday the launch of JORNAY PM (methylphenidate HCI extended-release capsules) in Canada, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children 6-12 years of age.
- The company had entered into an agreement with Ironshore Pharmaceuticals & Development, a wholly owned subsidiary of Ironshore Therapeutics, for JORNAY PM, approved in November 2024 to start distribution in Canada and Latin America.
Knight Therapeutics announces launch of JORNAY PM
5 hours ago
1
Related
Motorola Solutions raises 2025 EPS guidance and targets $12....
9 minutes ago
0
Werner signals $45M cost savings target on track while tight...
19 minutes ago
0
Illumina outlines path to high single-digit revenue growth a...
19 minutes ago
0
ResMed outlines high single-digit growth targets for mask se...
29 minutes ago
0
Merit Medical targets $175M free cash flow in 2025 with upda...
29 minutes ago
0
Arthur J. Gallagher signals full-year organic growth above 6...
39 minutes ago
0
Axos projects low to mid-teens annual loan growth in FY26 as...
39 minutes ago
0
Entegris plans capex reduction and free cash flow improvemen...
39 minutes ago
0
Cloudflare outlines $3B annualized revenue target for Q4 202...
49 minutes ago
0
Alphatec raises 2025 revenue guidance to $760M while advanci...
49 minutes ago
0
Alignment Healthcare outlines 20% membership growth target f...
49 minutes ago
0
Grid Dynamics outlines 300 bps margin expansion and $50M sha...
59 minutes ago
0
SPX Technologies anticipates $50M Olympus Max bookings and r...
59 minutes ago
0
Popular
English (US) · © FBT Company 2025. All rights are reserved